Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes
dc.contributor.author | Bressler, Neil M. | |
dc.contributor.author | Veith, Miroslav | |
dc.contributor.author | Hamouz, Jan | |
dc.contributor.author | Ernest, Jan | |
dc.contributor.author | Zalewski, Dominik | |
dc.contributor.author | Studnicka, Jan | |
dc.contributor.author | Vajas, Attila | |
dc.contributor.author | Papp, András | |
dc.contributor.author | Vogt, Gábor | |
dc.contributor.author | Luu, James | |
dc.contributor.author | Matuskova, Veronika | |
dc.contributor.author | Yoon, Young Hee | |
dc.contributor.author | Pregun, Tamás | |
dc.contributor.author | Kim, Taehyung | |
dc.contributor.author | Shin, Donghoon | |
dc.contributor.author | Oh, Inkyung | |
dc.contributor.author | Jeong, Hansol | |
dc.contributor.author | Kim, Mercy Yeeun | |
dc.contributor.author | Woo, Se Joon | |
dc.date.accessioned | 2023-07-12T09:41:31Z | |
dc.date.available | 2023-07-12T09:41:31Z | |
dc.date.issued | 2023 | |
dc.date.oa | 2023-08-04 | |
dc.date.pasync | 2023-07-27T23:14:06Z | |
dc.date.updated | 2023-07-12T09:41:31Z | |
dc.description.corrector | kzs | |
dc.identifier.citation | British Journal Of Ophthalmology. -107 : 3 (2023), p. 384-391. -Br. J. Ophthalmol. - 0007-1161 | |
dc.identifier.doi | http://dx.doi.org/10.1136/bjophthalmol-2021-319637 | |
dc.identifier.issn | 0007-1161 | |
dc.identifier.opac | https://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM113320 | |
dc.identifier.scopus | 85148479419 | |
dc.identifier.uri | https://hdl.handle.net/2437/357452 | |
dc.identifier.url | https://bjo.bmj.com/lookup/doi/10.1136/bjophthalmol-2021-319637 | |
dc.identifier.wos | 000723337800001 | |
dc.language | eng | |
dc.rights.access | open access article | |
dc.rights.owner | szerző | |
dc.subject.mab | Orvostudományok | |
dc.subject.mab | Klinikai orvostudományok | |
dc.title | Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes | |
dc.type | folyóiratcikk | |
dc.type | idegen nyelvű folyóiratközlemény külföldi lapban |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- FILE_UP_5_Biosimilar SB11 versus reference.pdf
- Méret:
- 558.42 KB
- Formátum:
- Adobe Portable Document Format
- Leírás:
- kiadói változat